Featuring: publicly traded & venture capital companies on the U.S. (NYSE, NASDAQ, AMEX & OTC: BB) and Canadian (TSX & TSX-V) stock exchanges, Investment & Money Management Ideas. |
|
|
Press Release - Telik, Inc. (TELK-NASDAQ) |
|
|
“Telik is a biopharmaceutical company focused on using its proprietary drug discovery technology (called TRAP™) to enable us to identify small molecule drug candidates that could be developed as treatments for a wide variety of cancers. All of our drug candidates were discovered internally using TRAP and this continues to be our vision since we joined the company in 1997.” - Dr. Michael M. Wick, M.D., Ph.D. (TELK) (Interview published March 7, 2008) |
The Most Powerful Name In Corporate News and Information. |
|
CURRENT ISSUE | COVER ARCHIVES | INDEX | CONTACT | FINANCIALS | MARKETING SERVICES | HOME PAGE |
|
PALO ALTO, Calif., May 1 /PRNewswire-FirstCall/ -- Telik, Inc. (Nasdaq: TELK) announced that its 2008 first quarter conference call and webcast will be held on Thursday, May 8, 2008 at 4:30 p.m. Eastern time (1:30 p.m. Pacific time) following the release earlier that day of the company's financial results for the first quarter ended March 31, 2008. The conference call will be accessible via Telik's website at http://www.telik.com or by telephone at 800-230-1085 or 612-332-1214. An archive of the conference call will be available on the Telik website or by telephone at 800-475-6701 or 320-365-3844, access code 920773. The archive will be available from approximately 6:30 p.m. Eastern time on May 8 through May 20, 2008. Telik, Inc. of Palo Alto, CA, is a biopharmaceutical company focused on discovering, developing and commercializing novel small molecule drugs to treat serious diseases. The company's most advanced investigational drug candidates in clinical development are TELINTRA(R), a modified glutathione analog for the treatment of cytopenias due to myelodysplastic syndrome or chemotherapy, and TELCYTA(R), a tumor-activated prodrug for the treatment of advanced ovarian cancer and non-small cell lung cancer. Telik's product candidates were discovered using its proprietary drug discovery technology, TRAP(R), which enables the rapid and efficient discovery of small molecule drug candidates. Additional information is available at http://www.telik.com.
SOURCE Telik, Inc. -0- 05/01/2008 /CONTACT: Patricia P. Frias, Corporate Communications of Telik, Inc., +1-650-845-7927, pfrias@telik.com/ /Web site: http://www.telik.com / (TELK)
|
|
